StockData
Virax Biolabs Group Ltd logo

Virax Biolabs Group Ltd (VRAX) stock

VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 6, 2026Score 9/30
$0.45−0.16 (-26.87%)

Close on Nov 16, 2026Market cap $259.49KP/E –Yield –

Virax Biolabs cash

Cash and short-term investments held at the end of each period.

Virax Biolabs's cash was $6.44M at Mar 31, 2026. For fiscal 2026 it was $6.44M, up 52.3% from the year before. The highest annual figure on record is $9.35M in fiscal 2023.

Annual cash

PeriodPeriod endValueChange
FY2026Mar 31, 2026$6.44M+52.3%
FY2025Mar 31, 2025$4.23M+17.8%
FY2024Mar 31, 2024$3.59M-61.6%
FY2023Mar 31, 2023$9.35M+42888.3%
FY2022Mar 31, 2022$21.76K+23.5%
FY2021Mar 31, 2021$17.62K-22.1%
FY2020Apr 1, 2020$22.61K–

Quarterly cash

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ1 2026Mar 31, 2026$6.44M+29496.0%
Q4 FY2025CQ1 2025Mar 31, 2025$4.23M+23899.5%
Q4 FY2024CQ1 2024Mar 31, 2024$3.59M+15775.3%
Q4 FY2023CQ1 2023Mar 31, 2023$9.35M–
Q4 FY2022CQ1 2022Mar 31, 2022$21.76K–
Q4 FY2021CQ1 2021Mar 31, 2021$17.62K–
Q4 FY2020CQ1 2020Apr 1, 2020$22.61K–

More Virax Biolabs figures

See a number that looks wrong?